2-(2-Methylpiperidin-1-yl)acetamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2-Methylpiperidin-1-yl)acetamide
• 化学式: C₈H₁₆N₂O
• mdl: MFCD06114487
• 分子量: 156.23
• InChiKey: APOFMXCNXQMJNH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] INDOLE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS<br/>[FR] DERIVES D'INDOLE UTILISES COMME ANTAGONISTES DU RECEPTEUR DE L'HISTAMINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123716A1

  公开（公告）日：2005-12-29

  The present invention relates to compounds of formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式（I）的化合物，其中X、R1、R2、R3、R4和R5如描述和权利要求中所定义，并其药学上可接受的盐，以及制备这些化合物和含有它们的药物组合物。这些化合物对于治疗和/或预防与H3受体调节相关的疾病是有用的。
• [EN] NAPHTHALINE DERIVATIVES USEFUL AS HISTAMINE-3-RECEPTOR LIGANDS<br/>[FR] DERIVES DE LA NAPHTALINE UTILISES COMME LIGANDS DU RECEPTEUR 3 DE L'HISTAMINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005117865A1

  公开（公告）日：2005-12-15

  The present invention relates to compounds of formula (I) wherein A, R1 and R2 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式（I）的化合物，其中A，R1和R2如描述和索赔中所定义，以及其药学上可接受的盐，以及制备这些化合物和含有它们的药物组合物。这些化合物可用于治疗和/或预防与H3受体调节相关的疾病。
• PHARMACEUTICAL COMPOSITIONS CONTAINING QUINAZOLINE DERIVATIVES FOR TREATING AS SEROTONIN RECEPTOR ANTAGONIST
  申请人：NAM Ghil Soo

  公开号：US20090054433A1

  公开（公告）日：2009-02-26

  The present invention relates to a pharmaceutical composition containing one or more quinazoline compounds as an active ingredient, which has antagonistic activity against serotonin 5-HT 3 A and is effective for the prevention and treatment of central nervous system (CNS) diseases, including emesis, nausea, alcoholism, drug abuse, depression, compulsive neurosis, anxiety, seizure, Alzheimer's disease, Parkinson's disease, Huntington's chorea, psychosis, schizophrenia, suicidal tendency, sleep disorder, appetite disorder and migraine.

  本发明涉及一种药物组合物，其包含一种或多种喹唑啉化合物作为活性成分，具有对5-HT3A血清素拮抗活性，并且对预防和治疗中枢神经系统（CNS）疾病有效，包括呕吐、恶心、酗酒、药物滥用、抑郁症、强迫神经症、焦虑、癫痫、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、精神病、精神分裂症、自杀倾向、睡眠障碍、食欲障碍和偏头痛。
• [EN] PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA<br/>[FR] COMPOSES DE PYRAZOLOPYRIDINE DESTINES AU TRAITEMENT DE L'ANEMIE
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：WO1993025205A1

  公开（公告）日：1993-12-23

  (EN) The present invention relates to a pharmaceutical composition for the prevention and/or the treatment of anemia in a human being or an animal which comprises, as an active ingredient, a pyrazolopyridine compound of formula (I) wherein R1 is lower alkyl, etc, R2 is a group of formula (II) (wherein R4 is protected amino, etc, and R5 is hydrogen, etc); etc, and R3 is hydrogen, etc, or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier or excipient, etc.(FR) Composition pharmaceutique destinée à la prévention et/ou au traitement de l'anémie chez l'être humain ou chez l'animal. Cette composition comprend comme ingrédient actif un composé de pyrazolopyridine de la formule (I), dans laquelle R1 est un alkyle inférieur, etc.; R2 est un groupe de la formule (II), dans laquelle R4 est un amino protégé, etc. et R5 est l'hydrogène, etc.; etc. et R3 est l'hydrogène, etc.; ou un sel pharmaceutiquement acceptable de ce composé, mélangé à un excipient pharmaceutiquement acceptable, etc.

  本发明涉及一种药物组合物，用于预防和/或治疗人类或动物的贫血，其作为活性成分包含式（I）的吡唑啉并吡啶化合物，其中R1是低碳基等，R2是式（II）的基团（其中R4是保护氨基等，R5是氢等）等，R3是氢等，或其药学上可接受的盐与药学上可接受的载体或赋形剂等混合物。
• Indole derivatives as H3 inverse agonists
  申请人：McArthur Gatti Silvia

  公开号：US20050282864A1

  公开（公告）日：2005-12-22

  The present invention relates to compounds of formula I: wherein X, R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

  本发明涉及式I的化合物：其中X，R1，R2，R3，R4和R5如描述和权利要求中所定义，并且其药学上可接受的盐，以及制备这些化合物和含有它们的制药组合物。这些化合物对于与H3受体调节相关的疾病的治疗和/或预防是有用的。